Human Pharmacology and Abuse Potential of the Analgesic Buprenorphine: A Potential Agent for Treating Narcotic Addiction
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Buprenorphine was evaluated for its abuse potential and utility in treating narcotic addiction. The drug was morphine-like but was 25 to 50 times more potent than morphine and was longer-acting. Little if any physical dependence of clinical significance was produced by buprenorphine. The effects of morphine to 120-mg doses were blocked by buprenorphine, a blockade that persisted for 29 1/2 hours. In man, buprenorphine has less intrinsic activity than morphine, and as such, as a low abuse potential. Moreover, the drug has potential for treating narcotic addiction since it is acceptable to addicts, is long-acting, produces a low level of physical dependence such that patients may be easily detoxified, is less toxic than drugs used for maintenance therapy, and blocks the effects of narcotics.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The final maintaining treatment was the following: buprenorphine [27, 28], lithium [29], methylphenidate [30, 31], and delorazepam [32] together with weekly sessions of third generation of Cognitive Behavioural Therapy (CBT) with integration of Mindfulness and Acceptance and Commitment Therapy [33] (see Table 1).”
In the citing paper
“Buprenorphine’s ability to both induce and relieve opiate withdrawal was observed by Martin et al. in 1976”
From Maintenance Medication for Opiate Addiction: The Foundation of Recovery (2012) · cites this paper as [89]
Citations
Cites
Martin, W. R., Eades, C. G., Thompson, J. A., Huppler, R. E., & Gilbert, P. E. (1976) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30536-7 · Cited by 2,992
Statistical Method in Biological Assay.
Barton, D. E., & Finney, D. J. (1966) · Biometrika · doi:10.2307/2334099 · Cited by 813
AGONIST AND ANTAGONIST PROPERTIES OF BUPRENORPHINE, A NEW ANTINOCICEPTIVE AGENT
COWAN, A., LEWIS, J. W., & MACFARLANE, I. R. (1977) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1977.tb07532.x · Cited by 528
Naltrexone, an Antagonist for the Treatment of Heroin Dependence: Effects in Man
Martin, W. R. (1973) · Archives of General Psychiatry · doi:10.1001/archpsyc.1973.01750360022003 · Cited by 392
THE ANIMAL PHARMACOLOGY OF BUPRENORPHINE, AN ORIPAVINE ANALGESIC AGENT
COWAN, A., DOXEY, J. C., & HARRY, E. J. R. (1977) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1977.tb07533.x · Cited by 327
THE HUMAN PHARMACOLOGY AND ABUSE POTENTIAL OF N-ALLYLNOROXYMORPHONE (NALOXONE)
Jasinski, D. R., Martin, W. R., & Haertzen, C. A. (1967) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)27721-7 · Cited by 283
Self-citationMartin, W. R. (1973) · Archives of General Psychiatry · doi:10.1001/archpsyc.1973.01750320112017 · Cited by 264
Martin, W. R., & Jasinski, D. R. (1969) · Journal of Psychiatric Research · doi:10.1016/0022-3956(69)90007-7 · Cited by 259
Self-citationFraser, H. F., Van Horn, G. D., Martin, W. R., Wolbach, A. B., & Isbell, H. (1961) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)26118-3 · Cited by 232
Ling, W. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770060043007 · Cited by 211
Cited by
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub4 · Cited by 2,274
Neonatal Abstinence Syndrome after Methadone or Buprenorphine Exposure
Jones, H. E., Kaltenbach, K., Heil, S. H., Stine, S. M., Coyle, M. G., Arria, A. M., O'Grady, K. E., Selby, P., Martin, P. R., & Fischer, G. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005359 · Cited by 986
“Eye, ear, nose, or throat problems 12 (14) 15 (17) 1 (1) 1 (2)”
Strang, J., Volkow, N. D., Degenhardt, L., Hickman, M., Johnson, K., Koob, G. F., Marshall, B. D. L., Tyndall, M., & Walsh, S. L. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0137-5 · Cited by 639
A Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431802 · Cited by 623
Metadata
- Authors
- Jasinski, D. R.
- Corresponding author
- Jasinski, Donald R.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 1978-04-01
- Volume
- 35
- Issue
- 4
- Pages
- 501
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2063539450
- Cited by
- 782
- References
- 27
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 8 · 2023: 9 · 2022: 13 · 2021: 7 · 2020: 18 · 2019: 11 · 2018: 19 · 2017: 19 · 2016: 19 · 2015: 14 · 2014: 19 · 2013: 30 · 2012: 22
- FWCI
- 18.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of General Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- buprenorphine, abuse liability, drug addiction, opioid analgesics, morphine potency, physical dependence, opioid antagonism, opioid detoxification, opioid maintenance treatment, drug toxicity
- MeSH terms
- Adult, Blood Pressure, Buprenorphine, Clinical Trials as Topic, Dose-Response Relationship, Drug, Double-Blind Method, Euphoria, Humans, Male, Methadone, Middle Aged, Morphinans, Morphine, Naloxone, Narcotics, Pulse, Pupil, Receptors, Opioid, Substance Withdrawal Syndrome, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Human Pharmacology and Abuse Potential of the Analgesic Buprenorphine: A Potential Agent for Treating Narcotic Addiction. https://app.cochat.ai/papers/10.1001/archpsyc.1978.01770280111012
- The paper
- Jasinski, D. R. (1978). Human Pharmacology and Abuse Potential of the Analgesic Buprenorphine: A Potential Agent for Treating Narcotic Addiction. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.1978.01770280111012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.